Revenue segments as reported by the company.

Nutrition

Diagnostics

Established Pharmaceuticals

Medical Devices

Other

Revenue Segments

Gross Profit, Operating Income, and Net Income as a percentage of Revenue

Gross Margin

Operating Margin

Profit Margin

Margins

An operating expense is an expense a business incurs through its normal business operations. Often abbreviated as OPEX.

Amortization of intangible assets

Research and development

Selling, general, and administrative

Operating Expenses

Year over year growth in Revenue and Operating Expenses.

Revenue Y/Y

OpEx Y/Y

Growth

Shares outstanding refer to a company's stock currently held by all its shareholders, including share blocks held by institutional investors and restricted shares owned by the company's officers and insiders.

Outstanding Shares

Market Cap

Also known as Price/Sales Ratio. Calculated using Average market cap for the quarter / Annualized quarterly revenue.

Revenue Multiple

Abbott Labs

St. Jude Medical was an American global medical device company headquartered in Little Canada, Minnesota, U.S., a suburb of Saint Paul. The company had more than 20 principal operations and manufacturing facilities worldwide with products sold in more than 100 countries. The company was acquired by Abbott Laboratories in January 2017.

St. Jude Medical

Abbott Laboratories engages in the discovery, development, manufacture, and sale of health care products. It operates through the following business segments: Established Pharmaceutical Products, Diagnostic Products, Nutritional Products, and Medical Devices. The Established Pharmaceutical Products segment refers to the international sales of a line of branded generic pharmaceutical products. The Diagnostic Products segment markets diagnostic systems and tests for blood banks, hospitals, commercial laboratories, and alternate-care testing sites. The Nutritional Products segment caters to the worldwide sales of adult and pediatric nutritional products. The Medical Devices segment includes electrophysiology, heart failure, vascular and structural heart devices for the treatment of cardiovascular diseases, and diabetes care products for people with diabetes, as well as neuromodulation devices for the management of chronic pain and movement disorders. The company was founded by Wallace Calvin Abbott in 1888 and is headquartered in Abbott Park, IL.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Abbott Labs reports solid Q4 performance and eyes growth opportunities

Abbott Labs delivered a strong performance in Q4 2022, showcasing resilience and strategic focus amidst challenges in certain business segments.
The company's emphasis on innovation, product excellence, and market expansion positions it well for future growth and success.
While facing challenges like inflation and market restrictions, Abbott is actively pursuing opportunities for growth through new product launches and strategic investments.
Investors can be optimistic about Abbott's outlook for 2023, with a positive trajectory in sales, product development, and cash use priorities.

Abbott Labs surpasses Q1 earnings estimates, eyes growth opportunities

Abbott Labs exceeded earnings expectations with strong organic sales growth. Performance driven by Medical Devices, Established Pharmaceuticals, and Nutrition segments. Challenges include lower Diagnostics sales and uncertainties around COVID testing.

Abbott Labs excels in Q2 with strong sales growth and innovation

Abbott Labs delivered a strong performance in Q2 2023, driven by robust organic sales growth, successful product launches, and strategic market expansion initiatives across key business segments.
Despite challenges related to COVID testing demand decline and exchange rate impacts, Abbott's focus on innovation, market share recovery, and operational efficiency positions it well for sustained growth and profitability.
The company's strengths in diverse product offerings, market leadership in key segments, and opportunities for further expansion and innovation underscore its resilience and strategic vision in the healthcare industry.
By navigating challenges, leveraging strengths, and capitalizing on opportunities, Abbott is poised to maintain its growth trajectory, drive market leadership, and deliver value to shareholders and stakeholders.

Abbott Labs excels in Q3, eyes growth in China and innovation

Abbott Labs delivered robust performance across key segments, positioning well for sustained growth.
The company showcased strong sales growth, user adoption, and strategic readiness for future opportunities.
While challenges exist in market dynamics and cost management, Abbott remains optimistic about its outlook.
Overall, Abbott's Q3 results reflect a resilient business model and a focus on innovation and growth.

Abbott Labs surpasses 2023 expectations, poised for strong 2024 growth

Abbott Labs delivered impressive performance in 2023, exceeding expectations and showcasing strength across key segments. The company's diversified business model and strategic investments position it well for continued growth in 2024. Abbott's focus on sustainable growth, market share expansion, and innovation bode well for its future.

Abbott Labs excels in Q1, raises guidance on strong performance

Abbott Labs delivered a standout quarter with robust financial performance, strategic product launches, and optimistic guidance updates. Despite facing FX challenges, the company remains well-positioned for growth through innovation and market expansion.

Abbott Labs excels in Q2, raises guidance amid strong segment performance

Abbott Labs' Q2 performance reflects strong growth momentum across segments and strategic focus on innovation and market expansion.
The company's strengths in Nutrition, Diagnostics, and Medical Devices position it well for sustained growth and value creation.
While facing challenges such as ongoing litigation, Abbott Labs remains poised to capitalize on opportunities in biosimilars, new product approvals, and market expansion.

Abbott Labs excels in Q3 with strong sales growth and strategic advancements

Abbott Labs demonstrated robust financial performance and strategic advancements in Q3 2024, showcasing resilience and innovation. While facing potential challenges ahead, the company's diverse portfolio and market-leading products position it well for future growth and success.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Abbott Laboratories said Covid-related headwinds may actually be easing.

Abbott Labs shares pop as revenue, earnings defy steep drop in Covid test sales

Abbott Laboratories (ABT) Q1 2023 Earnings Call Transcript

Double-digit organic growth in Diabetes Care, Structural Heart, Heart Failure and Neuromodulation contributed to Abbott's (ABT) Q1 revenues.

Abbott's (ABT) Q1 Earnings Beat Estimates, Margins Down

Cigna

Elevance Health Inc

Labcorp Holdings Inc

Organon & Co

Pfizer

UnitedHealth Group

Viatris

Healthcare stocks have sputtered this year after performing well in 2022. A Barron's screen has identified stocks that are poised to outperform for the rest of the year.

8 Defensive Plays as Healthcare Stocks Stumble

It is no surprise that Abbott Laboratories (NYSE: ABT) produce a solid quarter. Med-tech companies like Intuitive Surgical (NASDAQ: ISRG), Boston Scientific (NYSE: BSX) and DexCom (NASDAQ: DXCM) have seen an increase in analyst interest driven by results and outlook.

Diversified Abbott Laboratories Could Reverse And Move Higher

Abbott (ABT) came out with quarterly earnings of $1.03 per share, beating the Zacks Consensus Estimate of $0.98 per share. This compares to earnings of $1.73 per share a year ago.

Abbott (ABT) Beats Q1 Earnings and Revenue Estimates

Abbott Laboratories (NYSE:ABT)' first quarter earnings topped expectations with growth in business segments such as medical devices offsetting a sharp decline in Covid-19 test sales, sending its shares higher in pre-market trading. The Chicago-based medical products company posted adjusted earnings per share of $1.03, above the consensus expectation per FactSet of $0.99.

Abbott Laboratories weathers Covid-19 test slowdown to report forecast topping 1Q profit

Abbott Laboratories reported better-than-expected first-quarter sales despite a slowdown from its Covid test segment. ABT stock jumped.

Abbott Labs Shakes Off Covid Test Decline To Top First-Quarter Estimates

Visa

Abbott Laboratories and Visa are both leaders in their respective fields. Abbott Laboratories is a serial innovator, a factor that will help it maintain solid financial results.

2 Stocks That Could Help Make You a Millionaire by Retirement

The company beat analysts' expectations with first-quarter earnings of $1.03 a share on sales of $9.75 billion.

Abbott Labs' Sales, Earnings Defy Slowdown in Covid-19 Tests. Stock Rises.

Abbott Laboratories stock ABT, -0.35% rose 2% in premarket trade Wednesday, after the diagnostics and medical device company beat earnings estimates for the first quarter, although declining sales of COVID tests continued to weigh. The company posted net income of $1.318 billion, or 75 cents a share, down from $2.447 billion, or $1.37 a share, in the year-earlier period.

Abbott Labs stock up 2% premarket after earnings beat despite declining COVID testing sales

Sales of $9.7 billion driven by strong underlying base business performance Reported sales decreased 18.1 percent due to anticipated decline in COVID-19 testing-related sales versus prior year Organic sales growth for underlying base business of 10.0 percent, led by Medical Devices, Established Pharmaceuticals and Nutrition ABBOTT PARK, Ill., April 19, 2023 /PRNewswire/ -- Abbott (NYSE: ABT) today announced financial results for the first quarter ended March 31, 2023.

Abbott Reports First-Quarter 2023 Results; Increases Outlook For Underlying Base Business

ASML Hld

Baker Hughes Co

Morgan Stanley

In mid-morning trading on Monday, the Dow Jones industrials were up 0.04% while the S&P 500 was down 0.07% and the Nasdaq 0.22% lower.

Earnings Previews: Abbott Labs, ASML, Baker Hughes, Morgan Stanley

Abbott (ABT) receives the FDA clearance for a standalone reader to be used for the FreeStyle Libre 3 iCGM system.

Abbott (ABT) Gets FDA Clearance for FreeStyle Libre 3 Reader

More Medicare beneficiaries than ever before who are living with diabetes and use insulin1 will now be eligible for reimbursement when using Abbott's (NYSE: ABT) FreeStyle Libre® portfolio3,4 – the most prescribed and affordable continuous glucose monitoring system (CGM) in the United States

Abbott's FreeStyle Libre® Continuous Glucose Monitoring Systems Obtain Significantly Expanded Coverage for Medicare Beneficiaries

ABBOTT PARK, Ill., April 14, 2023 /PRNewswire/ -- Abbott (NYSE: ABT) today announced that the U.S. Food and Drug Administration (FDA) has cleared a reader for its FreeStyle Libre® 3 integrated continuous glucose monitoring (iCGM) system, which features the world's smallest, thinnest and most discreet5 glucose sensor.

FDA Clears Reader for Abbott's FreeStyle Libre® 3 System

Abbott will see a decline in sales given the forex headwinds and lower Covid-19-related testing demand.

What To Expect From Abbott's Q1?

Abbott (ABT) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Earnings Preview: Abbott (ABT) Q1 Earnings Expected to Decline

Gorman-Rupp

Leggett & Platt

Lowe's

Altria

MSA Safety

Nordson

S&P Global

Stanley Black & Decker

Sysco

Tennant

The 49 Dividend Kings collectively lost 1 basis point in March but retained a positive year-to-date return. The 12 best dividend kings selected for March, based on forecasted growth and valuation, underperformed the average dividend king return by 32 bps.

My 12 Best Dividend Kings For April 2023

Apple

Automatic Data Processing

Ameriprise Financial

Best Buy

Blackstone Group

Comcast

CME Group

CVS Health

Enterprise Products Partners

Fidelity National Information

Global Payments

Home Depot

Intel

Johnson & Johnson

Nexstar Media Group

Realty Income Corp

PepsiCo

Prudential Financial

Schwab US Dividend Equity ETF

Charles Schwab

Toronto-Dominion Bank

Tractor Supply

The portfolio remains at record high levels of cash holdings, which is fine for the first time in a long time, cash is providing a decent return. Income growth is projected at 7.9% for the year, up from last month. This was primarily due to including an estimated return on cash.

My Dividend Growth Portfolio March Update: Still Accumulating Cash

AbbVie

Accenture Plc

Agree Realty

American Financial Group

American Financial Group Inc 6 1/4 % Debentures 2014-30.9.54 Subord

Air Lease

Alamo Group

Alerus Financial Corp

American Tower

Amphenol

Alexandria Real Estate Equities

BancFirst

A weekly summary of dividend activity for Dividend Champions, Contenders, and Challengers. Companies which changed their dividends.

Dividend Champion, Contender, And Challenger Highlights: Week Of April 9

News for Abbott Labs Stock (ABT)